A different take on protein degradation will enter human trials as Lycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, has refueled with $106.6 million.
The Series C, disclosed Monday morning, will fund lead programs in autoimmune and inflammatory diseases. The biotech is also still working with investor and partner Eli Lilly on up to five different targets in immunology and pain, a $1.6+ billion pact that was disclosed a few weeks before a $70 million Series B in the fall of 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.